Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04577313 · ClinicalTrials.gov registry record · NA
HIV Treatment Adherence Dose Determination Trial
A NA study of HIV Infections, sponsored by University of Connecticut.
- Recruiting
- Registry status
- NA
- Development phase
- 400
- Enrollment target
- 2
- Study locations
NCT04577313: Recruiting NA study of HIV Infections, sponsored by University of Connecticut.
NCT04577313 is a NA study of HIV Infections that is actively recruiting participants, run by University of Connecticut. The registered enrollment target is 400 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (10% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04577313, a NA study of HIV Infections, is actively recruiting participants, sponsored by University of Connecticut.
- RECRUITING
- Registry status
- NA
- Development phase
- 400 participants
- Enrollment target
- 2
- Study locations
Study Summary
The proposed research will conduct the first dose-determination trial to find the optimal number of behavioral counseling sessions (dose) needed to achieve and sustain optimal HIV treatment adherence. The results of this study will determine how much intervention is needed for whom and at what cost to guide health policy and implementation of behavioral interventions designed to improve durable viral suppression.
Primary Outcome
Medication adherence defined by percentage of medication doses taken as prescribed
Conditions Studied
Interventions
- BEHAVIORAL Behavioral Self-Regulation Adherence Counseling
Study Locations (2)
Connecticut
- University of Connecticut - Storrs
Georgia
- University of Connecticut Field Site - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2026-11-30 |
| Phase | NA |
What NCT04577313 shows while recruiting
NCT04577313 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (10% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Behavioral Self-Regulation Adherence Counseling is the first listed.
NCT04577313 reports a single indexed study location in Connecticut, Georgia.
Frequently Asked Questions
What is clinical trial NCT04577313 about?
NCT04577313 is a clinical study titled "HIV Treatment Adherence Dose Determination Trial". The proposed research will conduct the first dose-determination trial to find the optimal number of behavioral counseling sessions (dose) needed to achieve and sustain optimal HIV treatment adherence. The results of this study will determine how much intervention is needed for whom and at what cost ...
What is the current status of trial NCT04577313?
This trial is currently recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2020-09-01. Estimated completion is 2026-11-30.
What conditions does trial NCT04577313 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT04577313?
The interventions under investigation include: Behavioral Self-Regulation Adherence Counseling (BEHAVIORAL).
Who is sponsoring clinical trial NCT04577313?
This trial is sponsored by University of Connecticut, which has 107 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04577313 being conducted?
This trial has 2 study locations across Connecticut, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04577313's enrollment target sits among peer trials
400 80th of 542 higher than 460 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI